^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Hansoh Xinfu (flumatinib)

    i
    Company:
    Jiangsu Hansoh Pharma, Jiangsu Hengrui Pharma
    Drug class:
    c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor
    Related drugs:
    Apply
    Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (HS-2020-07SZ) (NCT04739826)
    Phase N/A
    The First Affiliated Hospital of Soochow Univer...
    Recruiting
    Last update posted :
    11/03/2023
    Initiation :
    09/25/2020
    Primary completion :
    01/01/2025
    Completion :
    12/01/2025
    ABL1 • BCR
    |
    Tasigna (nilotinib) • Hansoh Xinfu (flumatinib)
    Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib (FINESTdm) (NCT04681820)
    Phase N/A
    Wuhan Union Hospital, China
    Recruiting
    Last update posted :
    08/01/2023
    Initiation :
    11/01/2020
    Primary completion :
    12/01/2023
    Completion :
    11/01/2024
    ABL1 • BCR
    |
    BCR-ABL1 V299L • BCR-ABL1 F317L • BCR-ABL1 M244V • BCR-ABL1 M351T • BCR-ABL1 H396R • BCR-ABL1 Q252H • BCR-ABL1 mutation • BCR-ABL1 E355G • BCR-ABL1 L387M • ABL1 F317L • ABL1 L387M • ABL1 M351T
    |
    dasatinib • imatinib • Tasigna (nilotinib) • Hansoh Xinfu (flumatinib)
    A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (NCT05367765)
    Phase 4
    Jiangsu Hansoh Pharmaceutical Co., Ltd.
    Not yet recruiting
    Last update posted :
    05/10/2022
    Initiation :
    04/30/2022
    Primary completion :
    04/30/2027
    Completion :
    04/30/2028
    ABL1 • BCR
    |
    imatinib • Hansoh Xinfu (flumatinib)
    A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. (NCT05353205)
    Phase 4
    Jiangsu Hansoh Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    04/29/2022
    Initiation :
    11/23/2021
    Primary completion :
    12/30/2022
    Completion :
    09/30/2025
    ABL1 • BCR
    |
    Hansoh Xinfu (flumatinib)
    Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid Leukemia (NCT04591197)
    Phase N/A
    Nanfang Hospital of Southern Medical University
    Recruiting
    Last update posted :
    04/12/2022
    Initiation :
    12/09/2020
    Primary completion :
    01/01/2024
    Completion :
    12/30/2024
    ABL1 • BCR
    |
    Hansoh Xinfu (flumatinib)
    Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure (NCT04677439)
    Phase 4
    Shenzhen Second People's Hospital
    Recruiting
    Last update posted :
    03/16/2022
    Initiation :
    01/01/2021
    Primary completion :
    05/30/2023
    Completion :
    12/30/2023
    ABL1 • BCR
    |
    imatinib • Hansoh Xinfu (flumatinib)
    Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL (NCT05071482)
    Phase 4
    wang, jianxiang
    Recruiting
    Last update posted :
    10/08/2021
    Initiation :
    09/16/2021
    Primary completion :
    10/30/2025
    Completion :
    10/30/2025
    ABL1 • BCR
    |
    imatinib • Hansoh Xinfu (flumatinib)